Liquidia Corp (NASDAQ: LQDA)

Liquidia Corp (LQDA) is a biopharmaceutical company that operates in the rare cardiopulmonary disease sector, with a particular focus on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company's primary business activities revolve around the development and commercialization of novel products using its proprietary PRINT particle engineering technology. This technology enables Liquidia to create highly uniform drug particles with precise control over their size, three-dimensional geometric shape, and chemical composition.

Liquidia generates revenue through a promotion agreement with Sandoz Inc. for the sale of Sandoz's substitutable generic treprostinil injection in the United States. The company, under the name Liquidia PAH, holds the exclusive rights to conduct commercial activities to encourage the appropriate use of treprostinil injection.

The company's lead product candidate is YUTREPIA, an inhaled dry powder formulation of treprostinil. YUTREPIA is designed to enhance deep lung delivery and achieve higher dose levels than the labeled doses of current inhaled therapies. This product has been tentatively approved by the FDA for the treatment of PAH and PH-ILD, and Liquidia is working to finalize the approval process.

Liquidia is also developing L606, an investigational, liposomal formulation of treprostinil administered twice-daily with a short-duration next-generation nebulizer. L606 is being evaluated in a clinical trial for the treatment of PAH and PH-ILD and is planned to be developed through the 505(b)(2) registration pathway.

The company's PRINT technology has been used to develop YUTREPIA and L606, with plans to use this technology for additional product developments in the future. Liquidia believes that its PRINT technology has the potential to revolutionize the way drugs are developed and manufactured, and the company is committed to using this technology to improve the lives of patients with rare and serious diseases.

The market for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease is significant, with estimated annual sales of over $5.5 billion in the United States. This market is expected to continue to grow as new treatments become available and more patients are diagnosed with these diseases. Liquidia is well-positioned to capitalize on this growth, with a pipeline of products that address unmet needs in the treatment of PAH and PH-ILD.

Liquidia's competitors include major multinational pharmaceutical companies, established biotechnology companies, biopharmaceutical companies, and generic drug companies. Many of these competitors have greater financial and other resources than Liquidia, such as more commercial resources, larger research and development staffs, and more extensive marketing and manufacturing organizations.

In terms of intellectual property, Liquidia owns or has exclusive licenses to a number of patents and patent applications related to its proprietary technology platform and product candidates. The company is pursuing additional patent protection for these and for its other product candidates and technology developments.